TransEnterix (NYSE:TRXC) said today that Italy’s Sofar SpA agreed to buy a $5 million stake in lieu of a $10 million milestone payment as the duo amended the $100 million deal for Sofar’s Telelap ALF-X robot-assisted surgery device – now known as Senhance. In September 2015, TransEnterix bought the Senhance technology for $25 million up front and about 15.5…